All In Biotech

Drug Trial Radar · NCT06452147

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial): A Pragmatic Multi-arm, Adaptive, Open Label, Multicenter Randomized Controlled Platform Trial to Assess the Effect of Different Enhanced Anesthesia Technique in Perioperative Neurocognitive Function, as Compared to Standard Anesthesia Care in the Elderly Patients Undergoing Hip Fracture

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,860 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,860

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

Jul 30, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zhejiang Provincial People's Hospital; First Affiliated Hospital of Wenzhou Medical University; Ningbo No.2 Hospital; Ningbo No.6 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University; Taizhou Hospital; Affiliated Wenling Hospital of Wenzhou Medical University; Lishui Country People's Hospital; The Fifth Hospital Affiliated to Wenzhou Medical University/ Lishui Central Hospital; Jinhua Municipal Central Hospital; Dongyang People's Hospital; People's Hospital of Quzhou
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The ANDES Platform Trial is a pragmatic, multicenter, adaptive randomized controlled platform trial in patients aged 65 years or older undergoing surgery for hip fracture. The trial evaluates whether enhanced anesthesia techniques reduce perioperative neurocognitive disorders compared with standard anesthesia care. The platform includes two randomization processes. In the first randomization, eligible participants are assigned to an active platform intervention-currently a preoperative regional nerve block or perioperative intravenous lidocaine infusion-or to a shared standard-anesthesia control. Participants for whom general anesthesia is planned may also enter a second, nested randomization and are assigned in a fixed 1:1 ratio to total intravenous anesthesia or volatile inhalational anesthesia, regardless of whether they participate in the first randomization. A non-surgical cognitive control cohort is included to characterize changes in cognitive test performance over time without exposure to surgery or study interventions. The Data Monitoring Committee reviews accumulating trial data and makes recommendations to the Trial Steering Committee, which determines whether platform interventions should continue, be modified, advance, or stop.

Conditions

  • Anesthesia
  • Hip Fractures
  • Dementia
  • Cognitive Impairment
  • Cognitive Decline

Interventions

  • Nerve blockProcedure

    Participants receive a preoperative regional nerve block as soon as possible after randomization. Ultrasound guidance is recommended, and fascia iliaca block is the recommended block technique.

  • Standard anesthesia careProcedure

    Standard anesthesia care consists of routine general or regional anesthesia according to usual practice at each study center. Participants randomized to the shared control group do not receive protocol-specified trial interventions unless otherwise required by the Trial Steering Committee. Changes to standard anesthesia care are made in accordance with the prespecified adaptive decision framework. The independent Data Monitoring Committee reviews accumulating data and makes recommendations to the Trial Steering Committee, which makes the final platform decisions.

  • Bupivacaine liposomeDrug

    For participants randomized to the nerve block group, 1.33% bupivacaine liposome is recommended as a long-acting local anesthetic, with a maximum dose not exceeding 133 mg, to maintain the continuity of the nerve block effect.

  • Regular local anestheticDrug

    For participants randomized to the nerve block group, regular local anesthetic, such as bupivacaine or ropivacaine, may be used with continuous electronic analgesic pump infusion or multiple single injections to maintain the continuity of the nerve block effect.

  • Intravenous infusion of lidocaineDrug

    Participants randomized to the lidocaine group receive ECG monitoring, oxygen saturation monitoring, blood pressure monitoring, and an open intravenous route on the morning of surgery. It is recommended to start the infusion of lidocaine as soon as possible in the ward. A portable electronic infusion pump is recommended for drug delivery. The loading dose is 1 mg/kg, and the maintenance dose range is 1 to 2 mg/kg/h. The specific dose is determined by the anesthesiologist according to the patient's condition. The infusion ends when the patient leaves the post-anesthesia care unit after surgery, and the infusion time and total amount are recorded. Intravenous infusion of lidocaine should be administered under ECG monitoring.

  • Total intravenous anesthesia maintenanceProcedure

    Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to total intravenous anesthesia maintenance in a 1:1 ratio. Total intravenous anesthesia maintenance is recommended to be mainly propofol-based, and analgesics such as remifentanil or fentanyl are recommended.

  • Volatile anesthesia maintenanceProcedure

    Among participants who are eligible under the master protocol and for whom general anesthesia is planned, anesthetic maintenance may be assigned by the second nested randomization to volatile anesthesia maintenance in a 1:1 ratio. Following intravenous induction, anesthesia maintenance mainly with sevoflurane or isoflurane is recommended.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Neurocognitive Disorders (NCD) events rate during the first 7 postoperative daysTime frame: during the first 7 postoperative days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Dongyang People's Hospital

    Dongyang, Zhejiang, China · Enrolling by invitation

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Enrolling by invitation

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China · Recruiting

  • Lishui Central Hospital, the Fifth Hospital Affiliated to Wenzhou Medical University

    Lishui, Zhejiang, China · Recruiting

  • Lishui People's Hospital

    Lishui, Zhejiang, China · Recruiting

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, China · Recruiting

  • Ningbo No.6 Hospital

    Ningbo, Zhejiang, China · Recruiting

  • Quzhou People's Hospital

    Quzhou, Zhejiang, China · Recruiting

  • Taizhou Central Hospital

    Taizhou, Zhejiang, China · Enrolling by invitation

  • Zhejiang Taizhou Hospital

    Taizhou, Zhejiang, China · Enrolling by invitation

  • The First People's Hospital of Wenling

    Wenling, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Enrolling by invitation

  • The Second Affilliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.